quarter results, we are increasing our fair value estimate for Exelixis to $2.70 per share from $2.10 due primarily to a lowering ..... clinical trial and the company's dwindling cash reserves, Exelixis faces an increasingly uncertain future. Cometriq revenue for
LONDON, Feb 17 (Reuters) - Tesco, Britain's biggest retailer, has named John Allan as its new chairman, succeeding Richard Broadbent who said in October he would step down in the wake of the supermarket's 263 million pounds ($403 million) profit overstatement.
Exelixis reported in-line third-quarter results and positive Phase II data for Cometriq ..... the clinical trial and the company’s rapidly dwindling cash reserves, Exelixis faces an uncertain future. Cometriq revenue for the quarter was $6.3
Exelixis and partner Roche reported positive detailed results for their Phase III study of MEK inhibitor cobimetinib in combination with
* Shares in Roche's biotech partner Exelixis jump 20 pct (Adds Exelixis share price jump, more on treatment debate)
Exelixis announced Monday that its key Phase III COMET-1 trial in men with metastatic ..... statistically significant (p value of 0.21). Based on the trial result, Exelixis plans to halt its clinical program in prostate cancer and reduce its workforce
Exelixis reported second-quarter results that were generally consistent with our ..... year and represent the major catalysts for the firm. During the quarter, Exelixis and partner Roche announced positive top-line results for their Phase
Exelixis and partner Roche have announced positive top-line results for their Phase ..... 50 per share fair value estimate and no-moat, stable trend rating for Exelixis , as we continue to await the more important Phase III results for Cometriq
Not much news on this one lately, depsite a big drop following Morningstar's latest reaffirmation. Still a Monringstar 5-star, but lots of shorts and mixed thoughts across traders. Just bought in at 3 and a quarter, so we'll see. Speculative at best at this point.
Exelixis reported first-quarter results that were generally consistent with our ..... this year and represent the major catalysts for the firm. In addition, Exelixis ’ partnered asset with Roche, MEK inhibitor GDC-0973 (in combination